Allelic variants of genes encoding for the Fc gamma receptors IIIA and IIA have been associated with the clinical response to cell‐depleting antibodies in lymphoma patients. Here, we tested the hypothesis that FCGR3A and FCGR2A high‐affinity polymorphisms predict clinical outcomes to alemtuzumab therapy in 85 patients with relapsing‐remitting multiple sclerosis. No differences in clinical and MRI‐based efficacy parameters, the development of severe infusion‐associated reactions and secondary autoimmune diseases during a 2 year follow‐up was observed based on FCGR3A or FCGR2A polymorphisms. This study does not support the use of FCGR genetic variants to predict clinical outcomes to alemtuzumab.

中文翻译：

---

FcγR变体对多发性硬化症中对alemtuzumab的反应的影响。

编码Fcγ受体IIIA和IIA的基因的等位基因变异与淋巴瘤患者对细胞消耗抗体的临床反应有关。在这里，我们测试了FCGR3A和FCGR2A高亲和力多态性预测85例复发缓解型多发性硬化症患者使用alemtuzumab治疗的临床结局的假说。基于FCGR3A或FCGR2A多态性，在2年的随访中，未观察到基于临床和MRI的疗效参数，严重的输液相关反应和继发性自身免疫性疾病的发展。这项研究不支持使用FCGR遗传变异来预测alemtuzumab的临床结果。